Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics Gets Septin9 Test Reimbursement in France

NEW YORK (GenomeWeb News) – Epigenomics today said that it a French supplementary insurance provider will provide coverage for the firm's Septin9 test for early detection of colorectal cancer.

The Berlin, Germany-based molecular diagnostics firm said that Mutuelle d’Assurance du Corps de Santé Français (MACSF) will reimburse €50 ($68.80) for the test.

MACSF offers additional health insurance to around 800,000 policy holders, according to Epigenomics. It is the second insurer in France to provide reimbursement for Septin9 testing, following a decision last year by Swiss Life to offer the test as part of its preventive health program.

Epigenomics' flagship product is its Epi proColon test, which is based on the Septin9 biomarker. The test is marketed in Europe, and the firm is awaiting a US Food and Drug Administration decision for marketing in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.